Aziyo Biologics Inc. (AZYO): Price and Financial Metrics


Aziyo Biologics Inc. (AZYO): $4.56

-0.29 (-5.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AZYO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AZYO is -4.44 -- better than only 3.1% of US stocks.
  • AZIYO BIOLOGICS INC's stock had its IPO on October 8, 2020, making it an older stock than only 11.3% of US equities in our set.
  • AZYO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.86% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AZIYO BIOLOGICS INC are INTZ, RENT, ATEC, BDSX, and AVYA.
  • AZYO's SEC filings can be seen here. And to visit AZIYO BIOLOGICS INC's official web site, go to www.aziyobiologics.com.

AZYO Valuation Summary

  • In comparison to the median Healthcare stock, AZYO's price/earnings ratio is 108.14% lower, now standing at -1.8.
  • Over the past 28 months, AZYO's price/earnings ratio has gone up 7.7.

Below are key valuation metrics over time for AZYO.

Stock Date P/S P/B P/E EV/EBIT
AZYO 2023-01-30 1.4 -6.0 -1.8 -3.0
AZYO 2023-01-27 1.3 -5.7 -1.7 -2.9
AZYO 2023-01-26 1.3 -5.7 -1.7 -2.9
AZYO 2023-01-25 1.4 -6.3 -1.8 -3.1
AZYO 2023-01-24 1.4 -6.2 -1.8 -3.1
AZYO 2023-01-23 1.3 -5.6 -1.6 -2.9

AZYO Price Target

For more insight on analysts targets of AZYO, see our AZYO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.5 (Moderate Buy)

AZYO Stock Price Chart Interactive Chart >

Price chart for AZYO

AZYO Price/Volume Stats

Current price $4.56 52-week high $9.01
Prev. close $4.85 52-week low $3.37
Day low $4.55 Volume 18,700
Day high $4.89 Avg. volume 39,392
50-day MA $4.25 Dividend yield N/A
200-day MA $6.18 Market Cap 62.81M

Aziyo Biologics Inc. (AZYO) Company Bio


Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.


AZYO Latest News Stream


Event/Time News Detail
Loading, please wait...

AZYO Latest Social Stream


Loading social stream, please wait...

View Full AZYO Social Stream

Latest AZYO News From Around the Web

Below are the latest news stories about AZIYO BIOLOGICS INC that investors may wish to consider to help them evaluate AZYO as an investment opportunity.

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on its team, portfolio, as well as the progress and achievements of its borrower partners.

Yahoo | January 31, 2023

Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know

Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | January 26, 2023

Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?

Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.

Yahoo | January 26, 2023

Investors in Aziyo Biologics (NASDAQ:AZYO) have unfortunately lost 38% over the last year

Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...

Yahoo | January 21, 2023

Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline Results

SILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary (unaudited) net sales results for its fourth quarter and full year ended December 31, 2022.

GlobeNewswire | January 9, 2023

Read More 'AZYO' Stories Here

AZYO Price Returns

1-mo 19.06%
3-mo -43.07%
6-mo -29.03%
1-year -16.94%
3-year N/A
5-year N/A
YTD 7.29%
2022 -32.54%
2021 -53.78%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8786 seconds.